ArticleThe Journal of biological chemistry2019
Target sequence requirements of a type III-B CRISPR-Cas immune system.
Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Identification and structure determination of a type III-Bv CRISPR complex that post-translationally modifies an associated toxin.Structure (London, England : 1993) · 2026Article
- Characterization of Five CRISPR Systems inInternational journal of molecular sciences · 2025Article
- Widespread CRISPR-derived RNA regulatory elements in CRISPR-Cas systems.Nucleic acids research · 2023Article
- Structure of theCurrent research in structural biology · 2023Article
- Article
- Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses.Nucleic acids research · 2022Article
- Reprogramming CRISPR-Mediated RNA Interference for Silencing of Essential Genes in Sulfolobales.Methods in molecular biology (Clifton, N.J.) · 2022Article
- The effect of crRNA-target mismatches on cOA-mediated interference by a type III-A CRISPR-Cas system.RNA biology · 2022Article
- Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector.Nucleic acids research · 2021Article
- PAM-repeat associations and spacer selection preferences in single and co-occurring CRISPR-Cas systems.Genome biology · 2021Article
- Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation.The Journal of biological chemistry · 2020Review
- CRISPR Tools To Control Gene Expression in Bacteria.Microbiology and molecular biology reviews : MMBR · 2020Review
- Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.Nucleic acids research · 2020Article
- The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling.eLife · 2020Article
- The Cyclic Oligoadenylate Signaling Pathway of Type III CRISPR-Cas Systems.Frontiers in microbiology · 2020Review
- Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.Nucleic acids research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
CRISPR-Cas systems are RNA-based immune systems that protect many prokaryotes from invasion by viruses and plasmids. Type III CRISPR systems are unique, as their targeting mechanism requires target transcription. Upon transcript binding, DNA cleavage by type III effector complexes is activated. Type III systems must differentiate between invader and native transcripts to prevent autoimmunity. Transcript origin is dictated by the sequence that flanks the 3' end of the RNA target site (called the PFS). However, how the PFS is recognized may vary among different type III systems. Here, using purified proteins and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.